Ponatinib-induced pneumonitis with severe acute respiratory distress syndrome
Ponatinib is a third-generation tyrosine kinase inhibitor (TKI) that can effectively treat patients with acute lymphoblastic leukaemia (ALL), particularly those with Philadelphia chromosome-positive (Ph+ALL) subtype, who are resistant or have previously received other TKIs. We report a case of a 42-...
Main Authors: | Sofia Dinis Ferreira, Margarida Jardim, Margarida Câmara, Fernando Jacinto, Fernando Aveiro, José Júlio Nóbrega |
---|---|
Format: | Article |
Language: | English |
Published: |
SMC MEDIA SRL
2023-11-01
|
Series: | European Journal of Case Reports in Internal Medicine |
Subjects: | |
Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/4162 |
Similar Items
-
Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia
by: Fabio Giglio, et al.
Published: (2023-01-01) -
Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
by: Valentina Giudice, et al.
Published: (2020-12-01) -
Non-Infectious Pneumonitis and Acute Respiratory Distress Syndrome in a Patient on Ustekinumab Treatment: Case Report and Literature Review
by: Valentina Cioffi, et al.
Published: (2024-03-01) -
Chronic Myeloid Leukaemia : A paradigm for malignancy or just a strange disease?
by: Shaun R. McCann
Published: (2012-11-01) -
Modern Management Options for Ph+ ALL
by: Josep-Maria Ribera, et al.
Published: (2022-09-01)